Nectar Lifesciences Buyback Nears Full Subscription; Demand Reaches 0.95x by January 2 Morning

Chandigarh, January 2, 2026 – Nectar Lifesciences Limited (NECLIFE) saw a sharp surge in participation in its ongoing share buyback, with the issue reaching 0.95 times subscription as of 9:20 a.m. on January 2, 2026, bringing it close to full subscription midway through the offer period.
The company is undertaking a fixed-price buyback of up to 3 crore equity shares at an offer price of ₹27 per share, with the offer window running from December 31, 2025 to January 6, 2026.

Buyback Snapshot​

Subscription Status​

(As on January 2, 2026 | 9:20 a.m.)
Against the total buyback size of 3 crore shares, cumulative bids for 2.85 crore shares have been received, translating into an overall subscription of 0.95 times.

Category-wise Demand Trend​

Strong Retail and Corporate Participation​

Individual investors led the demand with bids for 1.48 crore shares, reflecting sustained interest from retail participants. Demand from corporates under the non-institutional investor category also remained robust at 1.32 crore shares.

QIB Interest Picks Up​

Qualified Institutional Buyers bid for 4.43 lakh shares, marking a steady rise in institutional participation compared with earlier sessions.

Price-wise Order Book​

All bids so far have been placed in dematerialised form, with no physical share tenders reported.

About the Company​

Nectar Lifesciences Limited is a listed entity that has undergone a major strategic reset following the divestment of its pharmaceutical operating businesses in 2025. The current buyback reflects the company’s focus on returning surplus capital to shareholders and optimising its equity structure while it evaluates new business opportunities.